Entry Point Capital, LLC Replimune Group, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 8,051 shares of REPL stock, worth $83,488. This represents 0.11% of its overall portfolio holdings.
Number of Shares
8,051
Previous 17,704
54.52%
Holding current value
$83,488
Previous $145 Million
49.9%
% of portfolio
0.11%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding REPL
# of Institutions
153Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$104 Million1.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.24MShares$95.8 Million0.01% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$57.7 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$50.5 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$48.9 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $511M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...